JP2004352668A - Hypolipdemic agent containing mofezolac as active ingredient - Google Patents
Hypolipdemic agent containing mofezolac as active ingredient Download PDFInfo
- Publication number
- JP2004352668A JP2004352668A JP2003153185A JP2003153185A JP2004352668A JP 2004352668 A JP2004352668 A JP 2004352668A JP 2003153185 A JP2003153185 A JP 2003153185A JP 2003153185 A JP2003153185 A JP 2003153185A JP 2004352668 A JP2004352668 A JP 2004352668A
- Authority
- JP
- Japan
- Prior art keywords
- mofezolac
- hypolipdemic
- active ingredient
- administration
- total cholesterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【0001】
【産業上の利用分野】
本発明は、医薬として有用な血中脂質低下剤に関する。
【0002】
【従来の技術】
シクロオキシゲナーゼ−1(COX−1)選択的阻害剤としてモフェゾラク(Mofezolac)が知られている(非特許文献1、特許文献1参照)。モフェゾラクはCOX−1を阻害することにより、プロスタグランジンの生合成を抑制する作用を有する。この抑制作用により、消炎・鎮痛作用を発揮し、腰痛症、頚腕症候群、肩関節周囲炎、手術後・外傷後ならびに抜歯後の治療剤として汎用されている。しかしながら、これまでのところモフェゾラクが、血中脂質低下作用を有するとの報告はない。
【0003】
Apc1309ノックアウトマウス(Apc1309マウス)は家族性大腸腺腫症 (FAP) の疾患モデルマウスとして作製され、ヒトにおける大腸がんの発がんメカニズムの解析や化学予防剤の検索などに利用されている。Kitamuraらは、Apc1309マウスにCOX−1選択的阻害剤であるモフェゾラク (600ppm及び1,200ppm) を8週間混餌投与し、腸ポリープの数及び大きさに対する影響を検討した。その結果、腸ポリープ数はモフェゾラクの投与により用量依存的に減少し、1,200ppm投与群では対照群(基礎飼料投与群)の59% まで減少した。また、直径1.5mm以上のポリープ数の用量依存的な減少が認められた(非特許文献2、特許文献2参照)。
【0004】
【先行文献】
【非特許文献1】
Goto et. al.,
Prostaglandins & Other Lipid Mediators 56: 245−254, 1998
【非特許文献2】
Inhibitory effects of mofezolac, a cyclooxygenase−1 selective inhibitor, on intestinal carcinogenesis.
Carcinogenesis, 23: 1463−1466, 2002
【特許文献1】
特公昭61−6067号公報
【特許文献2】
特開2002−363079号公報
【0005】
【課題を解決するための手段】
一方、本発明者らの実験においてApc1309マウスの血清は乳濁しており、血清脂質関連パラメータ(トリグリセライド、総コレステロール)の顕著な上昇が認められたことから、APC遺伝子の変異と高脂血症及び大腸発がんの関連が示唆された。そこで、上記の実験群の中から各群6匹をランダムに選択し血清中トリグリセライド (TG)、総コレステロール (TC) 及び遊離脂肪酸 (FFA) を測定した。その結果、モフェゾラクの投与により血清中トリグリセライドは用量依存的に低下し、600ppm及び1,200ppm投与群でそれぞれ対照群の72%, 35%に低下した。総コレステロールは各群とも対照群の75%まで低下した。以上のことから、モフェゾラクの腸ポリープ抑制作用に本剤の血清脂質低下作用が関与している可能性が考えられた。
すなわち、本発明者らは、モフェゾラクが、血中脂質低下作用を有することを見出した。
本発明は、モフェゾラクまたはその誘導体を有効成分とする血中脂質低下剤を提供するものである。
その他の本発明は、モフェゾラクまたはその誘導体を有効成分とする高脂血症の予防及び治療薬を提供するものである。
【0006】
【発明の実施の形態】
本発明の有効成分であるモフェゾラク(化学名:[3,4−ジ(4−メトキシフェニル)−5−イソキサゾリル]−酢酸)は特公昭61−6067号公報に記載された方法によって合成することができる。
【0007】
本発明の有効成分としては、一般式
【化1】
(式中、R1、R2、及びR3は、それぞれ水素及び低級アルコキシから選ばれ、上記低級は直鎖又は分枝鎖の1ないし4の炭素原子の存在を意味する)で表される3,4−ジアリールイソキサゾール−5−酢酸を対象とする。また、本発明の有効成分は上記構造式で示した化合物に特に限定されず、血中の脂質低下作用を有する限り、モフェゾラクの誘導体、例えば、プロドラッグ(化学構造が修飾された結果、生体内で代謝されてはじめて活性を表わす薬物)を用いることも可能である。
【0008】
本発明の薬剤は、有効成分としてモフェゾラクまたはモフェゾラクの誘導体、あるいは医薬として許容されるそれらの塩類を含有するものであり、製剤化にあたっては、常法に従い必要に応じて薬学的に許容される担体を添加することができる。
【0009】
モフェゾラクまたはその誘導体の塩類としては、無機塩基塩等の塩基との塩、例えば、アルカリ金属塩(ナトリウム塩、カリウム塩等)、アルカリ土類金属塩(カルシウム塩、マグネシウム塩等)、アンモニウム塩等が挙げられる。さらに、有機塩基塩等の塩基との塩、例えば有機アミン塩(トリエチルアミン塩、ピリジン塩、ピコリン塩、エタノールアミン塩、トリエタノールアミン塩、ジシクロヘキシルアミン塩、N,N’−ジベンジルエチレンジアミン塩等)等の常用の無毒性塩類を例示することができる。さらに、本発明の有効成分は、本発明化合物及びその塩の水和物や溶媒和物及び結晶多形の物質をも包含する。
【0010】
本発明の薬剤は、血中脂質低下作用を有する。そのため、血中脂質の増加に基づく障害、例えばヒトの高脂血症などの予防及び治療に使用することができる。
【0011】
本発明の薬剤に含有し得る担体としては、例えば、界面活性剤、賦形剤、着色料、着香料、保存料、安定剤、緩衝剤、懸濁剤、等張化剤、結合剤、崩壊剤、滑沢剤、流動性促進剤、矯味剤等が挙げられるが、これらに制限されず、その他常用の担体を適宜使用することができる。具体的には、軽質無水ケイ酸、乳糖、結晶セルロース、マンニトール、デンプン、カルメロースカルシウム、カルメロースナトリウム、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース、ポリビニルアセタールジエチルアミノアセテート、ポリビニルピロリドン、ゼラチン、中鎖脂肪酸トリグリセライド、ポリオキシエチレン硬化ヒマシ油60、白糖、カルボキシメチルセルロース、コーンスターチ、無機塩類等を挙げることができる。
【0012】
本発明の薬剤の剤型としては、例えば、経口剤として錠剤、粉末剤、丸剤、散剤、顆粒剤、細粒剤、軟・硬カプセル剤、フィルムコーティング剤、ペレット剤、舌下剤、ペースト剤等、非経口剤として注射剤、坐剤、経皮剤、軟膏剤、硬膏剤、外用液剤等が挙げられ、当業者においては投与経路や投与対象等に応じた最適の剤型を選ぶことができる。
【0013】
以下に、製剤の処方例を挙げる。
散剤:モフェゾラク25mgおよび乳糖457mgを均一に混合することにより得る。
顆粒剤:モフェゾラク150mgおよび乳糖348mgに、1%ヒドロキシプロピルセルロース水溶液を少量加えて練合し造粒後、乾燥・整粒することにより得る。
錠剤:モフェゾラク100mgおよび結晶セルロース80mgを混合した後、更に精製水を添加し、練合してから乾燥・整粒する。次いで、カルメロースカルシウム8mgおよびステアリン酸マグネシウム2mgを加えて打錠することにより得る。
【0014】
本発明の薬剤の投与量は、剤型の種類、投与方法、患者の年齢や体重、患者の症状、血中脂質の増加に基づく障害の進行の程度等を考慮して、最終的には医師の判断により適宜決定されるものであるが、一般に大人では、1日当たり、モフェゾラクまたはモフェゾラク誘導体として25〜600mgを1〜数回に分けて経口投与することが好ましい。より好ましくは25〜400mg/日、更により好ましくは50〜200mg/日である。投与期間も、患者の治癒経過等に応じて適宜決定することが好ましい。
【0015】
【実施例】
以下、本発明を実施例により更に詳細に説明するが、本発明はこれら実施例に限定されるものではない。
【0016】
実験例 1
Apc1309ノックアウトマウス(Apc1309マウス)は家族性大腸腺腫症 (FAP) の疾患モデルマウスとして作製され、ヒトにおける大腸がんの発がんメカニズムの解析や化学予防剤の検索などに利用されている。本実験においてApc1309マウスの血清は乳濁しており、血清脂質関連パラメータ(トリグリセライド、総コレステロール)の顕著な上昇が認められた。
1群8匹の6週齢雄性Apc1309マウスにCOX−1選択的阻害剤であるモフェゾラク (600ppm及び1,200ppm) を8週間混餌投与し、腸ポリープの数及び大きさに対する影響を検討した。その結果、腸ポリープ数はモフェゾラクの投与により用量依存的に減少し、1,200ppm投与群では対照群(基礎飼料投与群)の59%まで減少した。また、直径1.5mm以上のポリープ数の用量依存的な減少が認められた。
一方、上記実験群の中から各群6匹をランダムに選択し血清中トリグリセライド (TG)、総コレステロール (TC) 及び遊離脂肪酸 (FFA) を測定した。その結果、表1に示した通り、モフェゾラクの投与により血清中トリグリセライドは用量依存的に低下し、600ppm及び1,200ppm投与群でそれぞれ対照群の72%、 35%に低下した。総コレステロールは各群とも対照群の75%まで低下した。以上のことから、モフェゾラクの腸ポリープ抑制作用に本剤の血清脂質低下作用が関与している可能性が考えられた。
なお、食餌摂取量はいずれの群も約3〜4gであり、8週間にわたり摂取量に変化はなかった。
【0017】
表1にモフェゾラク投与群における血清中の脂質レベルを示した。
【表1】
*: Significantly different from the control at P<0.05
a:Mean±S.E.
【0018】
参考までに、野生型マウスにおける血清脂質関連パラメータ(トリグリセライド、総コレステロール、遊離脂肪酸)は表2の通りであり、モフェゾラクは野生型マウスにおける血清脂質関連パラメータに対して有意な影響を及ぼさない。
【0019】
【表2】
【0020】
【発明の効果】
モフェゾラクはトリグリセリド及び総コレステロールをそれぞれ低下させることから、血中脂質低下剤として、高脂血症などの予防及び治療に使用することができる。また、モフェゾラクは腰痛症、頚腕症候群、肩関節周囲炎、手術後・外傷後ならびに抜歯後の治療剤として汎用されていることから、安全性も確立している。[0001]
[Industrial applications]
The present invention relates to a blood lipid lowering agent useful as a medicament.
[0002]
[Prior art]
Mofezolac is known as a cyclooxygenase-1 (COX-1) selective inhibitor (see Non-Patent Document 1 and Patent Document 1). Mofezolac has an effect of inhibiting the biosynthesis of prostaglandin by inhibiting COX-1. Due to this inhibitory effect, it exerts an anti-inflammatory and analgesic effect, and is widely used as a therapeutic agent for low back pain, neck-arm syndrome, periarthritis of the shoulder, post-operation / trauma, and post-extraction. However, there is no report so far that mofezolac has a blood lipid lowering effect.
[0003]
The Apc 1309 knockout mouse (Apc 1309 mouse) has been produced as a disease model mouse for familial adenomatous polyposis (FAP), and has been used for analyzing the carcinogenic mechanism of colorectal cancer in humans and searching for chemopreventive agents. Kitamura et al. Fed Afe 1309 mice with mofezolac (600 ppm and 1,200 ppm), a COX-1 selective inhibitor, for 8 weeks and examined the effect on the number and size of intestinal polyps. As a result, the number of intestinal polyps decreased in a dose-dependent manner by administration of mofezolac, and decreased to 59% in the 1,200 ppm administration group as compared with the control group (basal feed administration group). In addition, a dose-dependent decrease in the number of polyps having a diameter of 1.5 mm or more was observed (see Non-Patent Document 2 and Patent Document 2).
[0004]
[Prior literature]
[Non-patent document 1]
Goto et. al. ,
Prostaglandins & Other Lipid Mediators 56: 245-254, 1998
[Non-patent document 2]
Inhibitory effects of mofezolac, a cyclooxygenase-1 selective inhibitor, on intestinal carcinogenesis.
Carcinogenesis, 23: 1463-1466, 2002.
[Patent Document 1]
JP-B-61-6067 [Patent Document 2]
JP-A-2002-363079
[Means for Solving the Problems]
On the other hand, in the experiments of the present inventors, the serum of Apc 1309 mice was milky and a marked increase in serum lipid-related parameters (triglyceride, total cholesterol) was observed. And carcinogenesis in the large intestine were suggested. Therefore, 6 animals in each group were randomly selected from the above experimental groups, and triglyceride (TG), total cholesterol (TC) and free fatty acid (FFA) in serum were measured. As a result, the administration of mofezolac reduced the serum triglyceride in a dose-dependent manner, and decreased to 72% and 35% of the control group in the 600 ppm and 1200 ppm administration groups, respectively. Total cholesterol in each group was reduced to 75% of the control group. These results suggest that mofezolac may inhibit serum lipids in intestinal polyps.
That is, the present inventors have found that mofezolac has a blood lipid lowering effect.
The present invention provides a blood lipid lowering agent comprising mofezolac or a derivative thereof as an active ingredient.
Another object of the present invention is to provide a preventive and therapeutic agent for hyperlipidemia comprising mofezolac or a derivative thereof as an active ingredient.
[0006]
BEST MODE FOR CARRYING OUT THE INVENTION
Mofezolac (chemical name: [3,4-di (4-methoxyphenyl) -5-isoxazolyl] -acetic acid) as the active ingredient of the present invention can be synthesized by the method described in JP-B-61-6067. it can.
[0007]
The active ingredient of the present invention has a general formula:
Wherein R 1 , R 2 and R 3 are each selected from hydrogen and lower alkoxy, wherein said lower means the presence of 1 to 4 straight or branched chain carbon atoms. Intended for 3,4-diarylisoxazole-5-acetic acid. Further, the active ingredient of the present invention is not particularly limited to the compound represented by the above structural formula, and as long as it has a lipid lowering effect in blood, a derivative of mofezolac, for example, a prodrug (as a result of modification of the chemical structure, It is also possible to use a drug which shows an activity only after being metabolized in).
[0008]
The medicament of the present invention contains mofezolac or a derivative of mofezolac, or a pharmaceutically acceptable salt thereof as an active ingredient. Can be added.
[0009]
As salts of mofezolac or a derivative thereof, salts with bases such as inorganic base salts, for example, alkali metal salts (sodium salt, potassium salt, etc.), alkaline earth metal salts (calcium salt, magnesium salt, etc.), ammonium salts and the like Is mentioned. Further, salts with bases such as organic base salts, for example, organic amine salts (triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N, N'-dibenzylethylenediamine salt, etc.) And other commonly used non-toxic salts. Further, the active ingredient of the present invention also includes hydrates, solvates, and polymorphs of the compound of the present invention and salts thereof.
[0010]
The agent of the present invention has a blood lipid lowering effect. Therefore, it can be used for prevention and treatment of disorders based on an increase in blood lipids, for example, hyperlipidemia in humans.
[0011]
Carriers that can be included in the drug of the present invention include, for example, surfactants, excipients, coloring agents, flavors, preservatives, stabilizers, buffers, suspending agents, isotonic agents, binders, disintegrants Examples include, but are not limited to, agents, lubricants, fluidity promoters, flavoring agents, and the like, and other commonly used carriers can be used as appropriate. Specifically, light anhydrous silicic acid, lactose, crystalline cellulose, mannitol, starch, carmellose calcium, carmellose sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl acetal diethylaminoacetate, polyvinylpyrrolidone, gelatin, medium chain fatty acid triglyceride, Polyoxyethylene hydrogenated castor oil 60, sucrose, carboxymethyl cellulose, corn starch, inorganic salts and the like can be mentioned.
[0012]
As the dosage form of the drug of the present invention, for example, tablets, powders, pills, powders, granules, fine granules, soft and hard capsules, film coatings, pellets, sublinguals, pastes as oral preparations Parenteral preparations include injections, suppositories, transdermals, ointments, plasters, liquids for external use, etc., and those skilled in the art can select the optimal dosage form according to the administration route and administration subject. it can.
[0013]
Hereinafter, formulation examples of the preparation will be described.
Powder: obtained by uniformly mixing 25 mg of mofezolac and 457 mg of lactose.
Granules: obtained by adding a small amount of a 1% aqueous solution of hydroxypropylcellulose to 150 mg of mofezolac and 348 mg of lactose, kneading and granulating, followed by drying and sizing.
Tablet: After mixing 100 mg of mofezolac and 80 mg of crystalline cellulose, further add purified water, knead, and dry / granulate. Then, it is obtained by adding 8 mg of carmellose calcium and 2 mg of magnesium stearate and tableting.
[0014]
The dose of the drug of the present invention is ultimately determined by the In general, for adults, it is preferable to orally administer 25 to 600 mg of mofezolac or mofezolac derivative once or several times per day for adults. More preferably, it is 25 to 400 mg / day, still more preferably 50 to 200 mg / day. It is preferable that the administration period is appropriately determined according to the healing process of the patient.
[0015]
【Example】
Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples.
[0016]
Experimental example 1
The Apc 1309 knockout mouse (Apc 1309 mouse) has been produced as a disease model mouse for familial adenomatous polyposis (FAP), and has been used for analyzing the carcinogenic mechanism of colorectal cancer in humans and searching for chemopreventive agents. In this experiment, the serum of Apc 1309 mice was milky, and a marked increase in serum lipid-related parameters (triglyceride, total cholesterol) was observed.
A group of 6 6-week-old male Apc 1309 mice was administered a diet containing COF-1 selective inhibitor mofezolac (600 ppm and 1,200 ppm) for 8 weeks, and the effect on the number and size of intestinal polyps was examined. As a result, the number of intestinal polyps decreased in a dose-dependent manner by administration of mofezolac, and in the 1,200 ppm administration group, it decreased to 59% of the control group (basal feed administration group). In addition, a dose-dependent decrease in the number of polyps having a diameter of 1.5 mm or more was observed.
On the other hand, six animals were randomly selected from the above experimental groups, and triglyceride (TG), total cholesterol (TC) and free fatty acid (FFA) in serum were measured. As a result, as shown in Table 1, the administration of mofezolac reduced serum triglyceride in a dose-dependent manner, and in the 600 ppm and 1,200 ppm administration groups, respectively, to 72% and 35% of the control group. Total cholesterol in each group was reduced to 75% of the control group. These results suggest that mofezolac may inhibit serum lipids in intestinal polyps.
In addition, the food intake was about 3 to 4 g in all groups, and there was no change in the intake over 8 weeks.
[0017]
Table 1 shows serum lipid levels in the mofezolac administration group.
[Table 1]
* : Significantly differentiated from the control at P <0.05
a : Mean ± S. E. FIG.
[0018]
For reference, serum lipid-related parameters (triglyceride, total cholesterol, free fatty acids) in wild-type mice are as shown in Table 2, and mofezolac has no significant effect on serum lipid-related parameters in wild-type mice.
[0019]
[Table 2]
[0020]
【The invention's effect】
Mofezolac can reduce triglyceride and total cholesterol, respectively, and therefore can be used as a blood lipid lowering agent for prevention and treatment of hyperlipidemia and the like. Since mofezolac is widely used as a therapeutic agent for low back pain, cervical arm syndrome, shoulder periarthritis, post-operative / trauma, and post-extraction, safety has been established.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003153185A JP4754771B2 (en) | 2003-05-29 | 2003-05-29 | Blood lipid lowering agent containing mofezolac as an active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003153185A JP4754771B2 (en) | 2003-05-29 | 2003-05-29 | Blood lipid lowering agent containing mofezolac as an active ingredient |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004352668A true JP2004352668A (en) | 2004-12-16 |
JP4754771B2 JP4754771B2 (en) | 2011-08-24 |
Family
ID=34048211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003153185A Expired - Fee Related JP4754771B2 (en) | 2003-05-29 | 2003-05-29 | Blood lipid lowering agent containing mofezolac as an active ingredient |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4754771B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103998424A (en) * | 2011-12-15 | 2014-08-20 | 陶氏环球技术有限责任公司 | Process for preparing alkyl pyroglutamic acids |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS616067B2 (en) * | 1979-10-05 | 1986-02-24 | Shii Dee Shii Raifu Saienshizu Inc | |
JP2001233767A (en) * | 2000-02-25 | 2001-08-28 | Shionogi & Co Ltd | Apo ai expression sthenic agent |
JP2002363079A (en) * | 2001-05-31 | 2002-12-18 | National Cancer Center-Japan | Medicine for preventing or treating digestive tract polyp and/or digestive tract cancer containing mofezolac as active ingredient |
-
2003
- 2003-05-29 JP JP2003153185A patent/JP4754771B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS616067B2 (en) * | 1979-10-05 | 1986-02-24 | Shii Dee Shii Raifu Saienshizu Inc | |
JP2001233767A (en) * | 2000-02-25 | 2001-08-28 | Shionogi & Co Ltd | Apo ai expression sthenic agent |
JP2002363079A (en) * | 2001-05-31 | 2002-12-18 | National Cancer Center-Japan | Medicine for preventing or treating digestive tract polyp and/or digestive tract cancer containing mofezolac as active ingredient |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103998424A (en) * | 2011-12-15 | 2014-08-20 | 陶氏环球技术有限责任公司 | Process for preparing alkyl pyroglutamic acids |
Also Published As
Publication number | Publication date |
---|---|
JP4754771B2 (en) | 2011-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6843930B2 (en) | Nitrocatechol administration plan | |
KR101420319B1 (en) | Prophylactic and/or therapeutic agent for hyperlipemia | |
AU2011270726C1 (en) | Niacin mimetics, and methods of use thereof | |
JP2007523049A (en) | Antihyperlipidemic agent | |
AU2011270719B2 (en) | Niacin mimetics, and methods of use thereof | |
WO2006025378A1 (en) | Remedy for hyperlipemia | |
EA008108B1 (en) | Combination of a nsaid and a pde-4 inhibitors | |
JPH0761923A (en) | Therapeutic agent for alzheimer disease | |
JP5786714B2 (en) | Therapeutic or preventive agent for neuropathic pain | |
JPH0140009B2 (en) | ||
JP2004352668A (en) | Hypolipdemic agent containing mofezolac as active ingredient | |
US4855293A (en) | Anti-inflammatory compositions comprising a systemic non-steroidal anti-inflammatory drug and a cyclopentyl ether | |
TW415843B (en) | Anti-cancer pharmaceutical compositions comprising a diaminotrifluoromethylpyridine derivatives or the pharmaceutically acceptable salts thereof | |
JP6761347B2 (en) | Treatment for dyslipidemia | |
US20110034424A1 (en) | Method for the long term nsaid use | |
CA2684938A1 (en) | Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions | |
JP2011032262A (en) | Pharmaceutical composition for long term use of nsaid | |
JP4931598B2 (en) | Intestinal polyp inhibitor | |
JP2007137896A (en) | Ibuprofen-containing pharmaceutical preparation | |
TW202408499A (en) | Drugs that reduce myostatin in the blood | |
JPH04290824A (en) | Use of carbazone as novel therapeutically active component | |
JPWO2020080451A1 (en) | Renal fibrosis inhibitor in diabetic nephropathy | |
JP2002363079A (en) | Medicine for preventing or treating digestive tract polyp and/or digestive tract cancer containing mofezolac as active ingredient | |
WO2005117853A1 (en) | Therapeutic agent for hyperlipemia and therapeutic agent for diabetes | |
JP2002514208A (en) | Use of cyclooxygenase-2 inhibitors in the treatment and prevention of dementia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20030603 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20060330 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060405 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20060330 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091116 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091228 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100309 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100428 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20100507 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20100805 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100817 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100924 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110422 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20110526 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140603 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |